TELADOC HEALTH INC (TDOC)
US87918A1051 - Common Stock
Taking everything into account, TDOC scores 3 out of 10 in our fundamental rating. TDOC was compared to 40 industry peers in the Health Care Technology industry. TDOC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TDOC is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year TDOC has reported negative net income.
In the past year TDOC had a positive cash flow from operations.
In the past 5 years TDOC always reported negative net income.
TDOC had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
TDOC has a better Return On Assets (-5.39%) than 79.49% of its industry peers.
With a decent Return On Equity value of -10.18%, TDOC is doing good in the industry, outperforming 79.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.39% | ||
| ROE | -10.18% | ||
| ROIC | N/A |
ROA(3y)-107.27%
ROA(5y)-66.14%
ROE(3y)-201.33%
ROE(5y)-123.36%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 70.82%, TDOC is doing good in the industry, outperforming 69.23% of the companies in the same industry.
In the last couple of years the Gross Margin of TDOC has remained more or less at the same level.
TDOC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.82% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y0.46%
2. Health
2.1 Basic Checks
TDOC does not have a ROIC to compare to the WACC, probably because it is not profitable.
TDOC has more shares outstanding than it did 1 year ago.
TDOC has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, TDOC has an improved debt to assets ratio.
2.2 Solvency
TDOC has an Altman-Z score of -3.72. This is a bad value and indicates that TDOC is not financially healthy and even has some risk of bankruptcy.
TDOC has a worse Altman-Z score (-3.72) than 64.10% of its industry peers.
TDOC has a debt to FCF ratio of 7.72. This is a slightly negative value and a sign of low solvency as TDOC would need 7.72 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 7.72, TDOC is doing good in the industry, outperforming 64.10% of the companies in the same industry.
A Debt/Equity ratio of 0.67 indicates that TDOC is somewhat dependend on debt financing.
The Debt to Equity ratio of TDOC (0.67) is worse than 71.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.67 | ||
| Debt/FCF | 7.72 | ||
| Altman-Z | -3.72 |
ROIC/WACCN/A
WACC8.46%
2.3 Liquidity
TDOC has a Current Ratio of 3.82. This indicates that TDOC is financially healthy and has no problem in meeting its short term obligations.
TDOC's Current ratio of 3.82 is fine compared to the rest of the industry. TDOC outperforms 71.79% of its industry peers.
A Quick Ratio of 3.74 indicates that TDOC has no problem at all paying its short term obligations.
TDOC has a better Quick ratio (3.74) than 69.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.82 | ||
| Quick Ratio | 3.74 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 96.76% over the past year.
Looking at the last year, TDOC shows a small growth in Revenue. The Revenue has grown by 6.01% in the last year.
Measured over the past years, TDOC shows a very strong growth in Revenue. The Revenue has been growing by 44.17% on average per year.
EPS 1Y (TTM)96.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)6.01%
Revenue growth 3Y33.49%
Revenue growth 5Y44.17%
Sales Q2Q%2.69%
3.2 Future
TDOC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.48% yearly.
TDOC is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.97% yearly.
EPS Next Y18.82%
EPS Next 2Y24.05%
EPS Next 3Y17.08%
EPS Next 5Y15.48%
Revenue Next Year1.76%
Revenue Next 2Y2.68%
Revenue Next 3Y3.12%
Revenue Next 5Y3.97%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
TDOC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TDOC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
TDOC's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. TDOC is cheaper than 97.44% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, TDOC is valued cheaply inside the industry as 92.31% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.5 | ||
| EV/EBITDA | 4.56 |
4.3 Compensation for Growth
A more expensive valuation may be justified as TDOC's earnings are expected to grow with 17.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.05%
EPS Next 3Y17.08%
5. Dividend
5.1 Amount
TDOC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TELADOC HEALTH INC
NYSE:TDOC (6/14/2024, 7:04:00 PM)
After market: 10 0 (0%)10
+0.05 (+0.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.70B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.39% | ||
| ROE | -10.18% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.82% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.67 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.82 | ||
| Quick Ratio | 3.74 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)96.76%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y18.82%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)6.01%
Revenue growth 3Y33.49%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y